Effects of ２’-Fucosyllactose on Gut Health

doi:10.12281/ffs2708-1893-20210106-003

Abstract

Abstract: 2’-fucosyllactose (2’‐FL) is one of the most abundant oligosaccharides in breast milk of human, which is resistant to digestion and can reach the colon where it is fermented to affect intestinal health. 2’‐FL has been authorized to be used as a nutritional supplement for infant formula and ordinary food in America and Europe, but its application has not yet been approved in China. This paper aims to discuss the effect of 2’‐FL on the gut microbiota, intestinal barrier and intestinal immunity. A number of studies indicated that 2’‐FL reshape the composition of gut microbiota, especially by promoting the proliferation of Bifidobacterium. 2’‐FL maintains the intestinal barrier integrity by increasing the expression of intestinal epithelial tight junction protein and promoting the differentiation of intestinal epithelial cells. In addition, 2’‐FL has been shown to maintain the homeostasis of intestinal immunity and promote intestinal immunity maturation in both animal and clinical researches.

Key words: 2’-fucosyllactose, gut microbiota, intestinal barrier, intestinal immunity

CLC Number:

TS201.4

YAN Shikai, ZHAI Qixiao. Effects of ２’-Fucosyllactose on Gut Health[J]. Future Food Science, 2021, 1(2): 30-38.

References

[1] VANDENPLAS Y, BERGER B, CARNIELLI V P, et al. Human milk oligosaccharides: 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNnT) in infant formula[J]. Nutrients, 2018, 10(9): 1-16. DOI:10.3390/nu10091161. [2] BODE L. Human milk oligosaccharides: every baby needs a sugar mama[J]. Glycobiology, 2012, 22(9): 1147-1162. DOI:10.1093/glycob/cws074. [3] KONG Chunlin, CHENG Lianghui, KRENNING G, et al. Human milk oligosaccharides mediate the crosstalk between intestinal epithelial Caco-2 cells and Lactobacillus plantarum WCFS1 in an in vitro model with intestinal peristaltic shear force[J]. The Journal of Nutrition, 2020, 150(8): 2077-2088. DOI:10.1093/jn/nxaa162. [4] XIAO Ling, ENGEN P A, LEUSINK-MUIS T, et al. The combination of 2’-fucosyllactose with short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides that enhance influenza vaccine responses is associated with mucosal immune regulation in mice[J]. The Journal of Nutrition, 2019, 149(5): 856-869. DOI:10.1093/jn/nxz006. [5] CHLEILAT F, KLANCIC T, MA K, et al. Human milk oligosaccharide supplementation affects intestinal barrier function and microbial composition in the gastrointestinal tract of young Sprague Dawley rats[J]. Nutrients, 2020, 12(5): 1-19. DOI:10.3390/nu12051532. [6] MACPHERSON A J, AGüERO M G, GANAL-VONARBURG S C. How nutrition and the maternal microbiota shape the neonatal immune system[J]. Nature Reviews: Immunology, 2017, 17(8): 508-517. DOI:10.1038/nri.2017.58. [7] DONOVAN S M, COMSTOCK S S. Human milk oligosaccharides influence neonatal mucosal and systemic immunity[J]. Annals of Nutrition and Metabolism, 2016, 69(2): 42-51. DOI:10.1159/000452818. [8] ELISON E, VIGSNAES L K, RINDOM K L, et al. Oral supplementation of healthy adults with 2’-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota[J]. British Journal of Nutrition, 2016, 116(8): 1356-1368. DOI:10.1017/s0007114516003354. [9] REVERRI E J, DEVITT A A, KAJZER J A, et al. Review of the clinical experiences of feeding infants formula containing the human milk oligosaccharide 2’-fucosyllactose[J]. Nutrients, 2018, 10(10):1-11. DOI:10.3390/nu10101346. [10] FAIJES M, VILATERSANA M C, VAL-CID C, et al. Enzymatic and cell factory approaches to the production of human milk oligosaccharides[J]. Biotechnology Advances, 2019, 37(5): 667-697. DOI:doi.org/10.1016/j.biotechadv.2019.03.014. [11] OLIVEIRA D L, WILBEY R A, GRANDISON A S, et al. Milk oligosaccharides: a review[J]. International Journal of Dairy Technology, 2015, 68(3): 305-321. DOI:10.1111/1471-0307.12209. [12] ERNEY R M, MALONE W T, SKELDING M B, et al. Variability of human milk neutral oligosaccharides in a diverse population[J]. Journal of Pediatric Gastroenterology and Nutrition, 2000, 30(2): 181-192. DOI:10.1097/00005176-200002000-00016. [13] CHATURVEDI P, WARREN C D, ALTAYE M, et al. Fucosylated human milk oligosaccharides vary between individuals and over the course of lactation[J]. Glycobiology, 2001, 11(5): 365-372. DOI:10.1093/glycob/11.5.365. [14] KOBATA A, GINSBURG V. Oligosaccharides of human milk. 3. Isolation and characterization of a new hexasaccharide, lacto-N-hexaose[J]. Journal of Biological Chemistry, 1972, 247(5): 1525-1529. [15] AGOSTON K, HEDEROS M J, BAJZA I, et al. Kilogram scale chemical synthesis of 2’-fucosyllactose[J]. Carbohydrate Research, 2019, 476: 71-77. DOI:10.1016/j.carres.2019.03.006. [16] DENG Jieying, LV Xueqin, LI Jianghua, et al. Recent advances and challenges in microbial production of human milk oligosaccharides[J]. Systems Microbiology and Biomanufacturing, 2020, 1: 1-14. DOI:10.1007/s43393-020-00004-w. [17] ENGFER M B, STAHL B, FINKE B, et al. Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract[J]. American Journal of Clinical Nutrition, 2000, 71(6): 1589-1596. DOI:10.1093/ajcn/71.6.1589. [18] SALLI K, ANGLENIUS H, HIRVONEN J, et al. The effect of 2’-fucosyllactose on simulated infant gut microbiome and metabolites; a pilot study in comparison to GOS and lactose[J]. Scientific Reports, 2019, 9(1): 1-15. DOI:10.1038/s41598-019-49497-z. [19] BUNESOVA V, LACROIX C, SCHWAB C. Fucosyllactose and L-fucose utilization of infant Bifidobacterium longum and Bifidobacterium kashiwanohense[J]. BMC Microbiology, 2016, 16: 1-12. DOI:10.1186/s12866-016-0867-4. [20] KOSTOPOULOS I, ELZINGA J, OTTMAN N, et al. Akkermansia muciniphila uses human milk oligosaccharides to thrive in the early life conditions in vitro[J]. Scientific Reports, 2020, 10(1): 1-17. DOI:10.1038/s41598-020-71113-8. [21] WEICHERT S, JENNEWEIN S, HUFNER E, et al. Bioengineered 2’-fucosyllactose and 3-fucosyllactose inhibit the adhesion of pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory cell lines[J]. Nutrition Research, 2013, 33(10): 831-838. DOI:10.1016/j.nutres.2013.07.009. [22] ZHANG Guofang, ZHAO Jingjing, WEN Rong, et al. 2’-fucosyllactose promotes Bifidobacterium bifidum DNG6 adhesion to caco-2 cells[J]. Journal of Dairy Science, 2020, 103(11): 9825-9834. DOI:10.3168/jds.2020-18773. [23] YU Zhuoteng, NANTHAKUMAR N N, NEWBURG D S. The human milk oligosaccharide 2’-fucosyllactose quenches Campylobacter jejuni-induced inflammation in human epithelial cells Hep-2 and Ht-29 and in mouse intestinal mucosa[J]. Journal of Nutrition, 2016, 146(10): 1980-1990. DOI:10.3945/jn.116.230706. [24] WANG Yuanfei, ZOU Yan, WANG Jin, et al. The Protective effects of 2’-fucosyllactose against E. coli O157 infection are mediated by the regulation of gut microbiota and the inhibition of pathogen adhesion[J]. Nutrients, 2020, 12(5): 1-17. DOI:10.3390/nu12051284. [25] GRABINGER T, GLAUS GARZON J F, HAUSMANN M, et al. Alleviation of intestinal inflammation by oral supplementation with 2-fucosyllactose in mice[J]. Frontiers in Microbiology, 2019, 10: 1-14. DOI:10.3389/fmicb.2019.01385. [26] WEISS G A, CHASSARD C, HENNET T. Selective proliferation of intestinal Barnesiella under fucosyllactose supplementation in mice[J]. British Journal of Nutrition, 2014, 111(9): 1602-1610. DOI:10.1017/S0007114513004200. [27] LI Aili, NI Weiwei, LI Ying, et al. Effect of 2′-fucosyllactose supplementation on intestinal flora in mice with intestinal inflammatory diseases[J]. International Dairy Journal, 2020, 110: 1-10. DOI:10.1016/j.idairyj.2020.104797. [28] BERGER B, PORTA N, FOATA F, et al. Linking human milk oligosaccharides, infant fecal community types, and later risk to require antibiotics[J]. mBio, 2020, 11(2): 1-15. DOI:10.1128/mBio.03196-19. [29] MORROW A L, RUIZ-PALACIOS G M, ALTAYE M, et al. Human milk oligosaccharide blood group epitopes and innate immune protection against Campylobacter and Calicivirus diarrhea in breastfed infants[J]. Advances in Experimental Medicine and Biology, 2004, 554(3): 443-446. DOI:10.1007/978-1-4757-4242-8_61. [30] ZABEL B, YDE C C, ROOS P, et al. Novel genes and metabolite trends in Bifidobacterium longum subsp. infantis bi-26 metabolism of human milk oligosaccharide 2’-fucosyllactose[J]. Scientific Reports, 2019, 9(1): 1-11. DOI:10.1038/s41598-019-43780-9. [31] HIRVONEN J, SALLI K, PUTAALA H, et al. Selective utilization of human milk oligosaccharides 2’-fl and 3-fl by probiotic bacteria resulting in different metabolite production by these bacteria[J]. Current Developments in Nutrition, 2019, 3(1): 1771-1772. DOI:10.1093/cdn/nzz040.P20-012-19. [32] HESTER S. Individual and combined effects of nucleotides and human milk oligosaccharides on proliferation, apoptosis and necrosis in a human fetal intestinal cell line[J]. Food and Nutrition Sciences, 2012, 3: 1567-1576. DOI:10.4236/fns.2012.311205. [33] HOLSCHER H D, DAVIS S R, TAPPENDEN K A. Human milk oligosaccharides influence maturation of human intestinal Caco-2Bbe and HT-29 cell lines[J]. Journal of Nutrition, 2014, 144(5): 586-591. DOI:10.3945/jn.113.189704. [34] HOLSCHER H D, BODE L, TAPPENDEN K A. Human milk oligosaccharides influence intestinal epithelial cell maturation in vitro[J]. Journal of Pediatric Gastroenterology and Nutrition, 2017, 64(2): 296-301. DOI:10.1097/mpg.0000000000001274. [35] SODHI C P, WIPF P, YAMAGUCHI Y, et al. The human milk oligosaccharides 2’-fucosyllactose and 6’-sialyllactose protect against the development of necrotizing enterocolitis by inhibiting toll-like receptor 4 signaling[J]. Pediatric Research, 2020, 37: 667-697. DOI:10.1038/s41390-020-0852-3. [36] GOOD M, SODHI C P, YAMAGUCHI Y, et al. The human milk oligosaccharide 2’-fucosyllactose attenuates the severity of experimental necrotising enterocolitis by enhancing mesenteric perfusion in the neonatal intestine[J]. British Journal of Nutrition, 2016, 116(7): 1175-1187. DOI:10.1017/S0007114516002944. [37] EWASCHUK J B, DIAZ H, MEDDINGS L, et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function[J]. American Journal of Physiology: Gastrointestinal and Liver Physiology, 2008, 295(5): 1025-1034. DOI:10.1152/ajpgi.90227.2008. [38] HE Yingying, LIU Shubai, KLING D E, et al. The human milk oligosaccharide 2’-fucosyllactose modulates CD14 expression in human enterocytes, thereby attenuating LPS-induced inflammation[J]. Gut, 2016, 65(1): 33-46. DOI:10.1136/gutjnl-2014-307544. [39] COURTADE C L, HAN S, LEE S, et al. Attenuation of food allergy symptoms following treatment with human milk oligosaccharides in a mouse model[J]. Allergy, 2015, 70(9): 1091-1102. DOI:10.1111/all.12650. [40] XIAO Ling, LEUSINK-MUIS T, KETTELARIJ N, et al. Human milk oligosaccharide 2’-fucosyllactose improves innate and adaptive immunity in an influenza-specific murine vaccination model[J]. Frontiers in Immunology, 2018, 9:1-16. DOI:10.3389/fimmu.2018.00452. [41] AZAGRA B I, MASSOT C M, MAYNERIS P J, et al. Immunomodulatory and prebiotic effects of 2’-fucosyllactose in suckling rats[J]. Frontiers in Immunology, 2019, 10: 1-14. DOI:10.3389/fimmu.2019.01773. [42] MATSUKI T, YAHAGI K, MORI H, et al. A key genetic factor for fucosyllactose utilization affects infant gut microbiota development[J]. Nature Communications, 2016, 7(5): 1-12. DOI:10.1038/ncomms11939. [43] NAITO Y, UCHIYAMA K, TAKAGI T. A next-generation beneficial microbe: Akkermansia muciniphila[J]. Journal of Clinical Biochemistry and Nutrition, 2018, 63(1): 33-35. DOI:10.3164/jcbn.18-57. [44] DONG Ping, YANG Yi, WANG Weiping. The role of intestinal Bifidobacteria on immune system development in young rats[J]. Early Human Development, 2010, 86(1): 51-58. DOI:10.1016/j.earlhumdev.2010.01.002. [45] GOEHRING K C, MARRIAGE B J, OLIVER J S, et al. Similar to those who are breastfed, infants fed a formula containing 2’-fucosyllactose have lower inflammatory cytokines in a randomized controlled trial[J]. Journal of Nutrition, 2016, 146(12): 2559-2566. DOI:10.3945/jn.116.236919. [46] WU Jiayi, WU Shaohui, HUO Jinhong, et al. Systematic characterization and longitudinal study reveal distinguishing features of human milk oligosaccharides in china[J]. Current Concepts in Nutrition, 2020, 4(8): 1-10. DOI:10.1093/cdn/nzaa113. [47] Food and drug administration. Sub-chronic (13-week) oral toxicity study with 2’-fucosyllactose in rats[EB/OL]. (2017.8.16) [2020-12-26]. https://www.fda.gov/media/115456/download.

ISSN: 2708-1893